EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Isocitrate dehydrogenase-mutant astrocytoma in persons aged 55 years and older: Survival differences versus the young

Zainab Siddiq, Ahmed Gilani iD, Timothy H Ung, Bette K Kleinschmidt-DeMasters

Journal of Neuropathology & Experimental Neurology · 01.07.2025 · 84 (7) · 611-616

DOI: 10.1093/jnen/nlaf024 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Neuropathology & Experimental Neurology, online erschienen am 28.03.2025. Verfasst von Zainab Siddiq und 3 weiteren Autor:innen. Beteiligte Einrichtung: Colorado School of Public Health, University of Colorado, Aurora, CO, United States. Hauptthemen laut MEDLINE: Astrocytoma, Isocitrate Dehydrogenase, Brain Neoplasms, Mutation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Isocitrate dehydrogenase (IDH)-mutant astrocytomas show a peak incidence in young and middle-aged adults and have relatively favorable outcomes. In patients with these tumors ≥55 years at diagnosis, clinical, histopathologic, and prognostic characteristics are less clear. Here, we compared histopathological, immunohistochemical, molecular, and overall survival of 34 patients aged ≥55 years with a group of 84 patients aged 19-54 years; all had IDH mutant astrocytomas. The older cohort had 14 World Health Organization (WHO) grade 2, 7 WHO grade 3, and 13 WHO grade 4 tumors versus 24, 32, and 28 WHO grade 2, 3, and 4 tumors in the younger group. Comparing equal-grade tumors in both cohorts, Kaplan-Meyer survival analysis revealed that patients ≥55 years of age showed worse prognosis despite receiving comparable treatment regimens (Stupp protocol). Roughly equal numbers of noncanonical IDH mutations were seen in both groups (11.76% in ≥55 vs 19.04% in <55). Older patients were more likely to show retention of nuclear protein alpha-thalassemia and mental retardation X-linked syndrome (ATRX) and/or absence of strong P53 staining by immunohistochemistry. Although patients ≥55 years of age with astrocytomas, IDH-mutant, had worse overall survival, many, particularly those with low-grade tumors, had 5 years or greater survival. Employing parallel treatment regimens with chemotherapy, radiation, and maximum safe resection may improve survival of older patients with IDH mutant gliomas.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AstrocytomaIsocitrate DehydrogenaseBrain NeoplasmsMutationHumansMiddle AgedMaleAdultFemaleYoung AdultAgedAge FactorsCohort Studies

Stichwörter der Autor:innen

ATRXIDH-mutantastrocytomabrain tumormolecular diagnosticsoutcome

Substanzen

Isocitrate Dehydrogenase

Autor:innen und Institutionen

  • Colorado School of Public Health, University of Colorado, Aurora, CO, United States.
  • Department of Pathology, University of Colorado Anschutz Medical Campus, Aurora, CO, United States.
  • Department of Pathology, Children's Hospital Colorado, Aurora, CO, United States.
  • Department of Neurosurgery, University of Colorado Anschutz Medical Campus, Aurora, CO, United States.
  • Department of Neurology, University of Colorado Anschutz Medical Campus, Aurora, CO, United States.

ORCID-Profile: Ahmed Gilani

Zitieren

APA

Siddiq, Z., Gilani, A., Ung, T. H., & Kleinschmidt-DeMasters, B. K. (2025). Isocitrate dehydrogenase-mutant astrocytoma in persons aged 55 years and older: Survival differences versus the young. Journal of Neuropathology & Experimental Neurology, 84(7), 611-616. https://doi.org/10.1093/jnen/nlaf024

Vancouver

Siddiq Z, Gilani A, Ung TH, Kleinschmidt-DeMasters BK. Isocitrate dehydrogenase-mutant astrocytoma in persons aged 55 years and older: Survival differences versus the young. Journal of Neuropathology & Experimental Neurology. 2025;84(7):611-616. doi:10.1093/jnen/nlaf024

BibTeX
@article{Siddiq2025,
  author = {Siddiq, Zainab and Gilani, Ahmed and Ung, Timothy H and Kleinschmidt-DeMasters, Bette K},
  title = {Isocitrate dehydrogenase-mutant astrocytoma in persons aged 55 years and older: Survival differences versus the young},
  journal = {Journal of Neuropathology & Experimental Neurology},
  year = {2025},
  volume = {84},
  number = {7},
  pages = {611--616},
  doi = {10.1093/jnen/nlaf024}
}
Kostenlos starten →